EVUSHELD Treatment

EVUSHELD for COVID-19

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make EVUSHELD available during the COVID-19 pandemic.

EVUSHELD is an investigational medicine used in adults and adolescents 12 years of age and older who weigh at least 88 pounds for preexposure prophylaxis for prevention of COVID-19.

EVUSHELD is for persons who are:

• not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2 and
• Who have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccination or
• For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID-19 vaccine ingredient(s).

EVUSHELD is administered by two intramuscular injections every 6 months.

EVUSHELD is current available at the following NYC Health + Hospital locations:

• NYC Health + Hospitals/Bellevue
• NYC Health + Hospitals/Kings County
• NYC Health + Hospitals/Queens

Community providers interested in referring their patients for EVUSHELD at NYC Health + Hospitals will need to either complete an eform or call 212 COVID-19.